Alpha 2.0
Login Register
» Authors » K Hatake

K Hatake

Explore the profile of K Hatake including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 204
Citations 1005
Followers 0
Related Specialties
Hematology
Oncology
Pharmacology
Top 10 Co-Authors
Y Miura
I Wakabayashi
K Muroi
K Motoyoshi
S Hishida
K Ozawa
H Tomizuka
T Izumi
Y Terui
M Yoshida
Published In
Rinsho Ketsueki
Lancet
Biochem Biophys Res Commun
Eur J Pharmacol
Exp Hematol
Affiliations
Soon will be listed here.
Recent Articles
1.
Induced Pluripotent Stem Cell-Derived Hematopoietic Embryoid Bodies Improve Mouse Status in Septic Peritonitis
Kasuda S, Kudo R, Yuui K, Sakurai Y, Hatake K
Bull Exp Biol Med . 2019 Mar; 166(5):667-670. PMID: 30903503
We examined the efficacy of embryoid bodies from 6-day induced pluripotent stem cells an in vivo sepsis model. Injection of embryoid bodies to septic mice improved the condition of their...
2.
Induced Pluripotent Stem Cell-Derived Hematopoietic Embryoid Bodies Secrete Sphingosine-1-Phosphate and Revert Endothelial Injury
Kasuda S, Kudo R, Yuui K, Sakurai Y, Hatake K
Bull Exp Biol Med . 2018 Apr; 164(6):775-779. PMID: 29658075
The possibility of sphingosine-1-phosphate production by induced pluripotent stem cells is examined to assess their potential in treatment of sepsis. The hematopoietic embryoid bodies were derived from the culture of...
3.
High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy
Kusano Y, Yokoyama M, Terui Y, Inoue N, Takahashi A, Yamauchi H, et al.
Blood Cancer J . 2017 Sep; 7(9):e614. PMID: 28960192
No abstract available.
4.
Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K, et al.
Blood Cancer J . 2017 May; 7(5):e561. PMID: 28498371
No abstract available.
5.
Low absolute peripheral blood CD4+ T-cell count predicts poor prognosis in R-CHOP-treated patients with diffuse large B-cell lymphoma
Kusano Y, Yokoyama M, Terui Y, Nishimura N, Mishima Y, Ueda K, et al.
Blood Cancer J . 2017 Apr; 7(4):e558. PMID: 28430176
The absolute peripheral blood lymphocyte count at diagnosis is known to be a strong prognostic factor in patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine...
6.
Establishment of optimized ELISA system specific for HLA-G in body fluids
Ouji-Sageshima N, Geraghty D, Ishitani A, Hatake K, Ito T
HLA . 2016 Nov; 88(6):293-299. PMID: 27797156
Recently, human leukocyte antigen-G (HLA-G) has been a focus in the field of reproductive immunology, tumor progression and transplantation, because of its inhibitory function as ligand to the inhibitory receptors...
7.
Lichenoid drug eruption associated with Bendamustine
Kusano Y, Terui Y, Yokoyama M, Hatake K
Blood Cancer J . 2016 Jun; 6(6):e438. PMID: 27341077
No abstract available.
8.
Ethanol attenuates vasorelaxation via inhibition of inducible nitric oxide synthase in rat artery exposed to interleukin-1β
Yuui K, Kudo R, Kasuda S, Hatake K
Hum Exp Toxicol . 2015 Oct; 35(9):938-45. PMID: 26500219
Nitric oxide produced by inducible nitric oxide synthase (iNOS) regulates sepsis-induced hypotension. During septic shock, interleukin (IL)-1β is synthesized in endothelial cells and smooth muscle cells by endotoxin. Ethanol (EtOH)...
9.
Abnormalities in chromosome 6q24 as a cause of early-onset, non-obese, non-autoimmune diabetes mellitus without history of neonatal diabetes
Yorifuji T, Matsubara K, Sakakibara A, Hashimoto Y, Kawakita R, Hosokawa Y, et al.
Diabet Med . 2015 Mar; 32(7):963-7. PMID: 25809823
Aims: Abnormalities in the imprinted locus on chromosome 6q24 are the most common causes of transient neonatal diabetes mellitus (6q24-related transient neonatal diabetes). 6q24-Related transient neonatal diabetes is characterized by...
10.
The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations
Mishima Y, Terui Y, Takeuchi K, Matsumoto-Mishima Y, Matsusaka S, Utsubo-Kuniyoshi R, et al.
Blood Cancer J . 2012 Jul; 1(4):e15. PMID: 22829136
C-terminal mutations of CD20 constitute part of the mechanisms that resist rituximab therapy. Most CD20 having a C-terminal mutation was not recognized by L26 antibody. As the exact epitope of...